A. Carlsson Research Ab

Teva Pharmaceuticals International Gmbh

Nsab, Filial Af Neurosearch Sweden Ab, Sverige

Neurosearch Sweden Ab

Nsab, Filial Af Neurosearch Sweden Ab

Integrative Research Laboratories Sweden Ab

Susanna Waters

Clas Sonesson

Nicholas Ross Waters

Joakim Tedroff

Ingela Marianne Svan

Lars Swanson

Fredrik Pettersson

Bengt Andersson

Ingela Marianne Svan, Legal Representative

Anders Kristoffer Lilja, Legal Representative

Liselott Lilja Rönnqvist, Legal Representative

Jenny Maria Carlberg, Legal Representative

Anders Kristoffer Lilja

Liselott Lilja Rönnqvist

Jenny Maria Carlberg

Nicholas Waters

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; Ris OSOCF, OSOCH, SOR, SOR, COR, NO, or CONHRand when X is CH or C Rmay also be CF, CN, F, Cl, Br, or I; Ris a C-Calkyl, an allyl, CHSCH, CHCHOCH, CHCHCHF, CHCF, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or &#x2014;(CH)&#x2014;R; Ris a C-Calkyl CF, or N(R); Ris a C-Ccycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed

Modulators of dopamine neurotransmission

The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.

Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; Ris CF, OSOCF, OSOCH, SOR, SOR, COR, CN, OR, NO, CONHR, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; Ris F, Cl, Br, I, CN, CF, CH, OCH, OH, and NH; Rand Rare independently H or a C-Calkyl; Ris a C-Calkyl, an allyl, CHSCH, CHCHOCH, CHCHCHF, CHCF, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or &#x2014;(CH)R; Ris a C-Ccycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; Ris a C-Calkyl, CF, or N(R), and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.

A 3-substituted 4-(phenyl-N-alkyl)-piperazine compound of the following formula: wherein Ris selected from the group consisting of OSOCF, OSOCH, SOR, COCF, COCHand COCHCH, wherein Ris as defined hereafter; Ris selected from the group consisting of C-Calkyls, allyl, CHCHCHF, CHCF, 3,3,3-trifluoropropyl and 4,4,4-trifluorobutyl; Ris selected from the group consisting of C-Calkyls, CF, and N(CH); with the proviso that when Ris SORand Ris a C-Calkyl, then Ris not CHCHOCH; or a pharmaceutically acceptable salt thereof are provided. Also, pharmaceutical compositions comprising the above compound and methods wherein the above compound is used for the treatment of various disorders are provided.

Growing community of inventors

Göteborg, Sweden

Susanna Waters